Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$1.44 - $2.29 $55,110 - $87,640
38,271 Added 33.61%
152,129 $244,000
Q3 2022

Nov 15, 2022

BUY
$1.86 - $3.01 $36,642 - $59,296
19,700 Added 20.92%
113,858 $238,000
Q2 2022

Aug 15, 2022

SELL
$1.46 - $3.55 $707,666 - $1.72 Million
-484,703 Reduced 83.73%
94,158 $199,000
Q1 2022

May 16, 2022

BUY
$2.66 - $6.63 $49,127 - $122,449
18,469 Added 3.3%
578,861 $1.96 Million
Q4 2021

Feb 14, 2022

BUY
$6.07 - $12.0 $133,837 - $264,588
22,049 Added 4.1%
560,392 $3.4 Million
Q3 2021

Nov 15, 2021

BUY
$6.79 - $13.9 $329,735 - $675,011
48,562 Added 9.92%
538,343 $3.79 Million
Q2 2021

Aug 16, 2021

BUY
$9.43 - $16.6 $1.59 Million - $2.79 Million
168,263 Added 52.33%
489,781 $6.73 Million
Q1 2021

May 17, 2021

BUY
$9.71 - $18.6 $263,704 - $505,138
27,158 Added 9.23%
321,518 $3.44 Million
Q4 2020

Feb 16, 2021

BUY
$3.91 - $12.28 $127,333 - $399,910
32,566 Added 12.44%
294,360 $3.56 Million
Q3 2020

Nov 10, 2020

BUY
$3.81 - $5.73 $118,822 - $178,701
31,187 Added 13.52%
261,794 $1.38 Million
Q2 2020

Aug 14, 2020

BUY
$3.53 - $6.12 $2,195 - $3,806
622 Added 0.27%
230,607 $1.13 Million
Q1 2020

May 11, 2020

BUY
$3.21 - $7.06 $738,251 - $1.62 Million
229,985 New
229,985 $864,000

About Evelo Biosciences, Inc.


  • Ticker EVLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,994,000
  • Description
  • Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hy...
More about EVLO
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.